Jaguar Gene Therapy
Jaguar Gene Therapy is a biotechnology company focused on developing AAV-based gene therapies for serious genetic diseases. The company operates state-of-the-art facilities in North Carolina and has received significant investment to advance its pipeline of investigational therapies.
Company Overview
Jaguar Gene Therapy is dedicated to advancing gene therapy solutions through the expertise and manufacturing capabilities of Advanced Medicine Partners, its wholly owned subsidiary. Jaguar leverages the AAV gene therapy platform to address serious diseases with significant unmet needs. The company has a commercial-scale GMP facility in Durham, North Carolina, and a Process Sciences Laboratory in Cary, North Carolina, to support its research and development efforts.
Gene Therapy Manufacturing
Jaguar Gene Therapy boasts a state-of-the-art gene therapy commercial manufacturing facility in Durham, North Carolina. This facility is designed to scale the production of commercially viable gene therapies. The company also operates a Process Sciences Laboratory in Cary, North Carolina, which focuses on developing products for preclinical studies. Jaguar employs scalable and commercially viable manufacturing processes that ensure the purity and efficacy of its gene therapy products.
Pipeline of Gene Therapies
Jaguar Gene Therapy is advancing a robust pipeline of investigational gene therapies. Key programs include JAG101 for Type 1 galactosemia, JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome, and JAG301 for Type 1 diabetes. These programs utilize AAV-based delivery methods and are aimed at restoring proper genetic function in patients with serious diseases.
Research and Collaboration
Jaguar Gene Therapy is committed to advancing its research through strategic partnerships. The company has research agreements in place with Emory University and the University of Utah for its JAG101 program and with Tulane University for its JAG301 program. These collaborations are vital in developing cutting-edge treatments and ensuring the success of its pipeline programs.
Funding and Investment
Jaguar Gene Therapy has garnered significant financial backing to support its mission. The company closed a $139 million Series B funding round co-led by Eli Lilly and Company and Deerfield Management. Additionally, Samsung Ventures and the JDRF T1D Fund have invested in Jaguar, indicating strong confidence in its potential to revolutionize gene therapy. These funds will further drive the development and commercialization of its gene therapy programs.